ライフサイエンスコーパス: pneumococcal polysaccharide

1 r the responses to pertactin and serotype 6B pneumococcal polysaccharide.

2 Four of the antibodies cross-reacted with pneumococcal polysaccharide.

3 f IgM memory cells in the immune response to pneumococcal polysaccharides.

4 pendent Ag LPS, and type II T-independent Ag pneumococcal polysaccharides.

5 65 to 86 years of age) adults in response to pneumococcal polysaccharide 4 (PPS4) and PPS14.

6 cells responsible for the production of anti-pneumococcal polysaccharide Ab has been unclear.

7 pendent humoral immune responses to isolated pneumococcal polysaccharide Ags and highlight the potent

8 d uninfected control subjects with 23-valent pneumococcal polysaccharide and tetanus toxoid vaccines.

9 ride standards were used for quantitation of pneumococcal polysaccharides and conjugates with confirm

10 or tetanus diphtheria combination, 23-valent pneumococcal polysaccharide, and for all vaccines combin

11 Tetanus toxoid, pneumococcal polysaccharide, and KLH vaccines as well as

12 s formed on immunization with thyroglobulin, pneumococcal polysaccharide, and ssDNA-methylated BSA.

13 normal concentrations of antibodies against pneumococcal polysaccharides, and better renal function

14 ter, two sets of latex particles coated with pneumococcal polysaccharides, and serotype-specific anti

15 but not those of anti-tetanus toxoid or anti-pneumococcal polysaccharide antibodies, fell significant

16 e of all immunoglobulins, IgG subclasses and pneumococcal polysaccharide antibodies.

17 The pneumococcal polysaccharide antibody response was impair

18 ss may reflect immune paralysis due to large pneumococcal polysaccharide antigen loads and/or a poten

19 generated antigen-specific IgM responses to pneumococcal polysaccharide antigens, whereas PC1(hi) ce

20 nce typing and a microarray for detection of pneumococcal polysaccharide capsule biosynthesis genes t

21 Levels of natural antibodies to the pneumococcal polysaccharide component phosphocholine wer

22 The recent development of pneumococcal polysaccharide conjugate vaccines has led t

23 Pneumococcal polysaccharide conjugate vaccines prevent p

24 ococcal vaccine in the elderly, we evaluated pneumococcal polysaccharide-derived oligosaccharides con

25 ed IgG Ab production after immunization with pneumococcal polysaccharides in mice with disruptions in

26 nd immune response in neonatal mice, using a pneumococcal polysaccharide of serotype 1 conjugated to

27 fection or intraperitoneal immunization with pneumococcal polysaccharide or 4-hydroxy-3-nitrophenyl-a

28 Conjugation of various serotypes of pneumococcal polysaccharide (PnPS) to carrier protein en

29 hat respond to vaccination with the purified pneumococcal polysaccharide (PPS) has been a topic of de

30 By contrast, pneumococcal polysaccharide (PPS) immunization protected

31 Previous studies indicate that Abs to pneumococcal polysaccharide (PPS) serotypes 1 and 6B hav

32 Remarkably, pneumococcal polysaccharide (PPS) vaccination alone indu

33 The current pneumococcal polysaccharide (PPS) vaccine is highly effe

34 viduals that respond poorly to the 23-valent pneumococcal polysaccharide (PPS) vaccine, Pneumovax, su

35 fference in levels of IgG antibodies against pneumococcal polysaccharide (PPS), older adults had lowe

36 sed combinatorial library cloning to isolate pneumococcal polysaccharide (PPS)-specific Fab fragments

37 onse to T cell-independent (TI) Ags, such as pneumococcal polysaccharide (PPS).

38 her mice were naive or immunized with native pneumococcal polysaccharide (PPS; Pneumovax23) or protei

39 independent Ig isotype responses to isolated pneumococcal polysaccharides (PPS) required TLR signalin

40 ected persons to respond to vaccination with pneumococcal polysaccharides (PPS).

41 ide comparable results for a large number of pneumococcal polysaccharide preparations.

42 Pneumococcal polysaccharide-protein conjugate vaccines e

43 It is not known whether pneumococcal polysaccharide-protein conjugated vaccines

44 Widespread use of conjugate pneumococcal polysaccharide-protein vaccines may alter t

45 CD40 monoclonal antibody to mice, along with pneumococcal polysaccharide, provides a substitute for T

46 The type II T-independent Ag pneumococcal polysaccharide response was enhanced approx

47 have a receptor that interacts with capsular pneumococcal polysaccharides, setting the stage for furt

48 lly, late recovering patients displayed less pneumococcal polysaccharide-specific immunoglobin M-prod

49 neumococcus cells are impaired in generating pneumococcal polysaccharide-specific responses and succu

50 ore they had developed antibody responses to pneumococcal polysaccharide, still failed to show a resp

51 GBS-III, biochemically identical to capsular pneumococcal polysaccharide type 14 (PPS14) of Streptoco

52 detailed antibody responses after 23-valent pneumococcal polysaccharide vaccination (23vPPV).

53 Pneumococcal polysaccharide vaccination compared with no

54 23-valent pneumococcal polysaccharide vaccination is ineffective i

55 in antigens were normal, but the response to pneumococcal polysaccharide vaccination was moderately i

56 rs are considering such a recommendation for pneumococcal polysaccharide vaccination.

57 A 23-valent unconjugated pneumococcal polysaccharide vaccine (23vP), routinely ad

58 7; Prevnar) in infancy followed by 23-valent pneumococcal polysaccharide vaccine (23vPPV; Pneumovax)

59 -treated patients had decreased responses to pneumococcal polysaccharide vaccine (57% of patients had

60 rted that the 7-valent diphtheria-conjugated pneumococcal polysaccharide vaccine (PCV7) is safe and i

61 administration of the heptavalent conjugated pneumococcal polysaccharide vaccine (PCV7) were also ass

62 We compared revaccination with 23-valent pneumococcal polysaccharide vaccine (PN23) with primary

63 vaccination or revaccination with 23-valent pneumococcal polysaccharide vaccine (PN23).

64 ther passive immunization with the 23-valent pneumococcal polysaccharide vaccine (Pneumovax(R) 23; PP

65 The 23-valent pneumococcal polysaccharide vaccine (Pneumovax) might pr

66 All received 23-valent pneumococcal polysaccharide vaccine (PPS).

67 dose 6 months later, and 1 dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) 1 month lat

68 gate vaccine (PCV13) compared with 23-valent pneumococcal polysaccharide vaccine (PPSV23) among US ad

69 ortions and incidence matching the 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-vale

70 usly vaccinated with >/= 1 dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) and had CD4

71 tion Practices has recommended the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for nonelde

72 PD), with the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for prevent

73 Although the 23-valent pneumococcal polysaccharide vaccine (PPSV23) protects ag

74 Controversy persists over the benefits of pneumococcal polysaccharide vaccine (PPV) for adults at

75 Revaccination of healthy adults with pneumococcal polysaccharide vaccine (PPV) within several

76 Twenty-three-valent pneumococcal polysaccharide vaccine (PPV-23), which cont

77 determine the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) among Navajo

78 The benefits of using the 23-valent pneumococcal polysaccharide vaccine (PPV23) are controve

79 grouped serotypes contained in the 23-valent pneumococcal polysaccharide vaccine (PPV23) decreased at

80 Since the 23-valent pneumococcal polysaccharide vaccine (PPV23) is less effe

81 In the United Kingdom, the 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommend

82 >/= 200 randomized to receive the 23-valent pneumococcal polysaccharide vaccine (PPV23) or placebo a

83 and are indications for receipt of 23-valent pneumococcal polysaccharide vaccine (PPV23).

84 umonia (n = 16) and healthy volunteers given pneumococcal polysaccharide vaccine (PPV; n = 14) or pne

85 licensed (23-valent, 25 microgram/serotype) pneumococcal polysaccharide vaccine (PV).

86 althy human adults with Pneumovax (23-valent pneumococcal polysaccharide vaccine [PPV23]), IgG anti-c

87 s, but it remains unclear whether use of the pneumococcal polysaccharide vaccine alters the overall r

88 697 received 23-valent pneumococcal polysaccharide vaccine and 695 received pla

89 All children received 23-valent pneumococcal polysaccharide vaccine at age 13 months.

90 Four of 16 patients in group 1 responded to pneumococcal polysaccharide vaccine compared with 14 of

91 Immunization with the pneumococcal polysaccharide vaccine does not prevent col

92 The pneumococcal polysaccharide vaccine elicited comparable

93 se findings support the effectiveness of the pneumococcal polysaccharide vaccine for the prevention o

94 Pneumococcal polysaccharide vaccine is recommended for e

95 However, the effect of pneumococcal polysaccharide vaccine on vascular events r

96 gate vaccine followed by 1 dose of 23-valent pneumococcal polysaccharide vaccine or a single dose of

97 udy murine immune responses to the 23-valent pneumococcal polysaccharide vaccine Pnu-Imune, both in v

98 The 23-valent pneumococcal polysaccharide vaccine was formulated to pr

99 rs after transplantation and the response to pneumococcal polysaccharide vaccine was significantly lo

100 eritoneal B1b compartment, immunization with pneumococcal polysaccharide vaccine yielded comparable a

101 rgeting high-risk groups was undertaken with pneumococcal polysaccharide vaccine, and subsequently ra

102 sera of people immunized with the 23-valent pneumococcal polysaccharide vaccine, we confirmed that h

103 ne response to that induced by the 23-valent pneumococcal polysaccharide vaccine, which has been the

104 9F, and 23F linked to CRM197, or a 23-valent pneumococcal polysaccharide vaccine.

105 with the conjugate vaccine compared with the pneumococcal polysaccharide vaccine.

106 re due to serotypes covered by the 23-valent pneumococcal polysaccharide vaccine.

107 were serotypes represented in the 23-valent pneumococcal polysaccharide vaccine.

108 lysaccharides used to formulate a polyvalent pneumococcal polysaccharide vaccine.

109 ates were serotypes that are included in the pneumococcal polysaccharide vaccine.

110 uded in the 7-valent conjugate and 23-valent pneumococcal polysaccharide vaccines accounted for 78 pe

111 the influence of Km and Gm allotype genes on pneumococcal polysaccharide vaccines.

112 ons manifest decreased antibody responses to pneumococcal polysaccharide vaccines.

113 long-lasting, impaired antibody responses to pneumococcal polysaccharide vaccines.